Latest Financial Results
Quarter Ended Apr 30, 2018
Stay informed and receive company updates straight to your inboxSign up today
OncoSec Medical Incorporated is a biopharmaceutical company developing its investigational Intratumoral IL-12 intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of Intratumoral IL-12 have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating Intratumoral IL-12 for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate Intratumoral IL-12 in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.